[{"address1": "6600 Dumbarton Circle", "city": "Fremont", "state": "CA", "zip": "94555", "country": "United States", "phone": "650 752 1300", "fax": "650 752 1301", "website": "https://www.personalis.com", "industry": "Diagnostics & Research", "industryKey": "diagnostics-research", "industryDisp": "Diagnostics & Research", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.", "fullTimeEmployees": 223, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christopher M. Hall", "age": 54, "title": "President, CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 963750, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Aaron L. Tachibana", "age": 62, "title": "CFO & COO", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 811000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen M. Moore J.D.", "age": 51, "title": "Senior VP & Chief Legal Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 597975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard  Chen M.D., M.S.", "age": 52, "title": "Executive VP of R&D and Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 800600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Russ B. Altman M.D., Ph.D.", "title": "Co-Founder and Member of Clinical & Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.", "age": 52, "title": "Co-Founder and Member of Clinical & Scientific Advisory Board", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael P. Snyder Ph.D.", "title": "Co-Founder and Member of Clinical & Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael J Fitzpatrick", "title": "Vice President of Worldwide Sales", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christian  Haudenschild Ph.D.", "title": "Senior Vice President of Genomic Laboratory Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephane  Mouradian Ph.D.", "title": "Senior Vice President of Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.7, "open": 4.71, "dayLow": 4.7, "dayHigh": 4.9486, "regularMarketPreviousClose": 4.7, "regularMarketOpen": 4.71, "regularMarketDayLow": 4.7, "regularMarketDayHigh": 4.9486, "beta": 1.921, "forwardPE": -3.798387, "volume": 313571, "regularMarketVolume": 313571, "averageVolume": 1025518, "averageVolume10days": 405150, "averageDailyVolume10Day": 405150, "marketCap": 310555744, "fiftyTwoWeekLow": 0.891, "fiftyTwoWeekHigh": 7.2, "priceToSalesTrailing12Months": 3.8806372, "fiftyDayAverage": 5.2853, "twoHundredDayAverage": 2.6104, "currency": "USD", "enterpriseValue": 209672832, "profitMargins": -1.01781, "floatShares": 28849814, "sharesOutstanding": 65935400, "sharesShort": 3118660, "sharesShortPriorMonth": 2265118, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0473, "heldPercentInsiders": 0.24099001, "heldPercentInstitutions": 0.60243, "shortRatio": 4.44, "shortPercentOfFloat": 0.0752, "impliedSharesOutstanding": 65935400, "bookValue": 2.116, "priceToBook": 2.225898, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -81452000, "trailingEps": -1.64, "forwardEps": -1.24, "pegRatio": 0.28, "enterpriseToRevenue": 2.62, "enterpriseToEbitda": -3.011, "52WeekChange": 3.9578948, "SandP52WeekChange": 0.39389753, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "PSNL", "underlyingSymbol": "PSNL", "shortName": "Personalis, Inc.", "longName": "Personalis, Inc.", "firstTradeDateEpochUtc": 1561037400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f81834ed-ba4e-3518-a347-74e71fee4b87", "messageBoardId": "finmb_139360745", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.71, "targetHighPrice": 9.0, "targetLowPrice": 4.0, "targetMeanPrice": 7.05, "targetMedianPrice": 7.25, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 86972000, "totalCashPerShare": 1.639, "ebitda": -69627000, "totalDebt": 46663000, "quickRatio": 2.927, "currentRatio": 3.314, "totalRevenue": 80027000, "debtToEquity": 41.562, "revenuePerShare": 1.59, "returnOnAssets": -0.23281, "returnOnEquity": -0.56494, "freeCashflow": -29782376, "operatingCashflow": -61255000, "revenueGrowth": 0.352, "grossMargins": 0.27761, "ebitdaMargins": -0.87004, "operatingMargins": -0.74814004, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]